Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could tiny stem cell particles help control diabetes?

NCT ID NCT07693036

Recruiting now Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial investigates whether exosomes—tiny particles from human umbilical cord stem cells—can safely improve blood sugar control in adults with type 2 diabetes. Participants receive weekly intravenous infusions of the exosome product or a control for eight weeks. The study measures changes in HbA1c, a key marker of long-term blood sugar levels, and monitors for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
human umbilical cord mesenchymal stem cell-derived exosomes (GoldenExo NATX)
What this could lead to
If successful, this could point toward a new way to improve blood sugar control and reduce diabetes complications without daily injections.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to everyone. Exosome therapy is experimental and could have unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES MELLITUS (T2DM)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University first Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.